



Hybrid Discovery at a glance

A research collaboration platform in development: bring evidence, expertise and research together while keeping identifiable patient data at its source.

Four connected divisions - planned

Vault: controlled research resources and anonymized views. Clinical: evidence-led professional collaboration. Trials: specific, understandable participation. AI: bounded research analysis and reviewed outputs.

A clear sharing boundary

Identifiable originals, contact information and linkage keys stay with their custodian. Only a prepared, assessed and specifically approved anonymized derivative is eligible for sharing. Outputs need separate scientific and privacy review.

Available foundations

The public website, corporate materials, Hybrid-ID sign-in into an empty workspace and fresh signed Federation membership verification. Native ledger anchoring is pending. A private fixed-fixture synthetic laboratory exercises narrow release controls; it is not a medical anonymization service.

What comes next

Confirm one custody and release contract; implement source-side preparation and bounded collaboration with synthetic material; validate denials, expiry, revocation and output review. Real-data readiness is a separate institutional and operational decision.

Who it is for

Research institutions and custodians, medical and academic researchers, clinical specialists, pharmaceutical and study teams, and future research participants. Each role retains specific responsibilities and permissions.

Informational corporate overview. No clinical authorization, dataset access, active study, validated medical service, compliance assurance, delivery date or financing offer is implied. No patient data or confidential research material should be submitted through the public website.